USE of RUXOLITINIB AS SECOND-LINE TREATMENT in PATIENTS with POLYCYTHAEMIA VERA: A MULTICENTRE STUDY

Authors
Category Primary study
Conference30th Congress of theEuropean Hematology Association Annual Congress, EHA2025
Year 2025
This article has no abstract
Epistemonikos ID: 8216c40bd545d2fecd5e8ad9d63377c32bf9e7cc
First added on: Nov 15, 2025